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false‐positive	 LAC	 conclusions	were	obtained	 at	 supratherapeutic	 enoxaparin	 and	
danaparoid	levels	only.	AC	may	prolong	APTT	screen	clotting	times,	requiring	3‐step	
testing	to	avoid	potential	misdiagnosis	of	LAC.
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1  | INTRODUCTION
Detection	 of	 lupus	 anticoagulant	 (LAC),	 as	 part	 of	 the	 laboratory	














treated	with	VKA,	 in	 pregnant	women	with	 a	 history	 of	 obstetric	
APS,	or	as	first‐line	treatment	in	catastrophic	APS.10	However,	pres‐
ence	of	heparins	 in	samples	admitted	to	the	clinical	 laboratory	for	














Current	 guidelines	 for	 laboratory	 detection	 of	 LAC	 issued	 by	
the	 International	Society	on	Thrombosis	and	Haemostasis	 (ISTH),2 
the	 Clinical	 and	 Laboratory	 Standards	 Institute,12	 and	 the	 British	
Committee	 for	 Standards	 in	 Haematology	 (BCSH)13 recommend 
caution	 when	 interpreting	 LAC	 tests	 in	 patients	 on	 heparins	 be‐
cause	 of	 the	 risk	 of	 false‐positive	 conclusions.	 The	 ISTH	 guide‐
line	 recommends	 performing	 LAC	 testing	 more	 than	 12	 hours	
after	 the	 last	 LMWH	 dose.	 The	 BCSH	 guideline	 states	 that	 LAC	
testing	 should	 not	 be	 performed	 in	 patients	 receiving	 therapeu‐
tic	doses	of	UFH,	while	prophylactic	UFH	or	LMWH	doses	should	
have	 less	 effect.	A	 recent	 survey	questionnaire	 performed	by	 the	
Scientific	and	Standardization	committee	for	Lupus	Anticoagulant/
Antiphospholipid	Antibodies	 of	 the	 ISTH	 showed	 that	 there	were	
a	variety	of	opinions	about	whether	and	when	to	 test	patients	on	
LMWH	or	UFH.14
For	 LAC	 detection	 in	 samples	 from	 patients	 on	 VKA	 treat‐
ment,	 the	 ISTH	 guideline	 provides	 International	 Normalized	





UFH,	 an	 LMWH	 (enoxaparin),	 and	 a	 heparinoid	 (danaparoid)	 on	
LAC	 assays	 over	 broad	 anti‐Xa	 activity	 ranges	 and	 to	 establish	








that	 this	approach	 is	able	 to	 remove	DOAC	from	plasma.16‒21 In 
this	 light,	 the	 second	aim	of	our	 study	was	 to	evaluate	whether	
AC	is	able	to	adsorb	heparins	and	heparinoids	and	neutralize	their	
effect	on	LAC	assays.
2  | MATERIALS AND METHODS
2.1 | Spiking experiment
Citrated	 whole	 blood	 (BD	 Vacutainer	 citrate	 3.2%,	 2.7	 mL;	 BD,	
Erembodegem,	 Belgium)	 was	 collected	 from	 15	 healthy	 volun‐
teers	 after	 informed	 consent.	 Normal	 pooled	 plasma	 (NPP)	 was	
obtained	 following	 double	 centrifugation	 at	 2230	 g	 for	 15	min‐
utes,	 stored	at	−80°C	and	 thawed	at	37°C	 for	5	minutes	before	
analysis.	 UFH	 (Heparine	 Leo	 100	 IU/mL	 solution	 for	 injection)	
was	purchased	 from	LEO	Pharma	 (Ballerup,	Denmark),	 enoxapa‐
rin	(Clexane	2000	IU	[20	mg]/0.2	mL	solution	for	 injection)	from	
Sanofi	(Diegem,	Belgium),	and	danaparoid	(Orgaran	750	IU/0.6	mL	
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2.2 | LAC testing and interpretation
According	 to	 current	 ISTH	 guidelines,2	 3‐step	 LAC	 testing	 was	
carried	 out	 in	 a	 dRVVT‐based	 and	 an	 APTT‐based	 test	 system.	








olamine	 (HPE)	 (Staclot	 LA,	 Stago)	 and	differences	between	 clot‐
ting	 times	measured	 in	 the	 absence	 and	 presence	 of	 HPE	were	
calculated.	For	dRVVT	confirmation	tests,	phospholipid‐rich	STA‐
Staclot	 DRVV	 Confirm	 reagent	 (Stago)	 was	 used.	 Mixing	 tests	





ting	 time	 ratios	 (NCRs)	 for	 screening,	 mixing,	 and	 confirmation	
assays.	 For	 individual	 test	 interpretation,	 NCRs	 were	 compared	




confirm	 ratio,	 1.10	 for	 dRVV	 screen	mix/confirm	mix	 ratio,	 1.35	
for	PTT‐LA	screen,	1.13	for	PTT‐LA	screen	mix,	and	8.00	seconds	
for	 Staclot	 LA.	 For	 the	 dRVVT	 system,	mixing	 and	 confirmation	
tests	were	performed	simultaneously	 if	NCRs	of	 screening	 tests	
exceeded	 cutoffs.	 For	 the	 APTT	 system,	mixing	 tests	were	 per‐
formed	first	when	screening	tests	were	prolonged.	Confirmation	










2.4 | Sample pretreatment with AC















3  | RESULTS AND DISCUSSION
3.1 | In vitro effect of UFH, enoxaparin, and 

















Abnormal	 APTT	 screening	 and	 mixing	 results	 were	 obtained	 at	
the	lowest	anti‐Xa	activity	levels	(0.1,	0.2,	and	0.6	anti‐Xa	IU/mL	
for	UFH,	enoxaparin,	 and	danaparoid,	 respectively).	 It	 should	be	
noted	that	the	PTT‐LA	screen	reagent	used	in	these	assays	does	
not	contain	a	heparin‐neutralizing	agent,	which	results,	for	exam‐
ple,	 in	 screening	 results	 outside	 the	 measurement	 range	 of	 the	




mal	 results	were	 obtained	 at	 high	 enoxaparin	 (starting	 from	2.5	
anti‐Xa	 IU/mL)	 and	danaparoid	 (starting	 from	1.9	 anti‐Xa	 IU/mL)	
levels.	 Interestingly,	 prolongation	 of	 Staclot	 LA	 clotting	 times	
by	 UFH	 seems	 to	 be	 phospholipid	 dependent	 as	 high	 UFH	 lev‐
els	 (starting	 from	1.6	 anti‐Xa	 IU/mL)	prolonged	 clotting	 times	 in	
the	 presence	 of	 hexagonal	 phase	 phospholipids	 to	 a	 higher	 ex‐
tent	than	clotting	times	in	the	absence	of	phospholipids.	This	re‐
sulted	 in	APTT	 confirmation	 results	 never	 exceeding	 the	 cutoff.	
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Danaparoid (anti-Xa IU/mL)
0.0 0.6 0.8 1.1 1.3 1.9 2.2
Danaparoid (anti-Xa IU/mL)
0.0 0.6 0.8 1.1 1.3 1.9 2.2
Danaparoid (anti-Xa IU/mL)
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0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.3 1.4 1.6 2.1 2.5 2.9
Enoxaparin (anti-Xa IU/mL)
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.3 1.4 1.6 2.1 2.5 2.9
Enoxaparin (anti-Xa IU/mL)
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.3 1.4 1.6 2.1 2.5 2.9
Enoxaparin (anti-Xa IU/mL)
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.3 1.4 1.6 2.1 2.5 2.9
0.0 0.1 0.4 0.5 0.8 1.0 1.3
UFH (anti-Xa IU/mL)
1.5 1.6 1.9 2.0 2.5 3.0
0.0 0.1 0.4 0.5 0.8 1.0 1.3
UFH (anti-Xa IU/mL)
1.5 1.6 1.9 2.0 2.5 3.0
0.0 0.1 0.4 0.5 0.8 1.0 1.3
UFH (anti-Xa IU/mL)
1.5 1.6 1.9 2.0 2.5 3.0
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UFH,	 enoxaparin,	 and	 danaparoid	 clearly	 affected	 LAC	 assays,	
especially	 APTT‐based	 tests,	 with	 abnormal	 screening	 and	 mix‐
ing	 tests	 in	 this	 test	 system	already	 seen	 at	 low	anti‐Xa	 activity	
levels.	However,	applying	 the	3‐step	procedure	 including	 results	
of	 confirmation	 tests,	 UFH	 did	 not	 result	 in	 false‐positive	 LAC,	
while	 enoxaparin	 as	 well	 as	 danaparoid	 caused	 false‐positive	














Screening ≥1.6 ≥1.4 ≥1.1
Mixing … ≥2.5 ≥1.3
Confirmation … … ≥1.9
Conclusion … … ≥1.9
(B)	APTT	system
Screening ≥0.1 ≥0.2 ≥0.6
Mixing ≥0.1 ≥0.2 ≥0.6
Confirmation … ≥2.5 ≥1.9








dRVVT screen (s) APTT screen(s)
Before AC After AC Before AC After AC
Neat	NPP … 32.5 31.5 35.6 35.3
UFH 0.1 41.1 40.4 64.5 78.3
0.4 43.7 42.1 109.8 140.5
0.8 44.0 44.6 245.2 298.0
1.3 43.0 43.7 >300.0 >300.0
2.0 204.1 254.1 >300.0 >300.0
Enoxaparin 0.2 39.3 43.7 47.8 49.6
0.4 38.6 39.6 54.8 59.8
0.8 43.1 39.8 74.2 79.2
1.2 48.0 43.4 93.9 101.1
2.1 62.0 67.9 145.1 191.5
Danaparoid 0.6 42.2 40.5 58.2 59.1
1.1 53.3 51.1 76.3 76.4
1.9 97.3 89.9 124.6 132.6
Abbreviations:	AC,	activated	carbon;	APTT,	activated	partial	thromboplastin	time;	dRVVT,	dilute	
Russell’s	viper	venom	test;	NPP,	normal	pooled	plasma;	UFH,	unfractionated	heparin.

















els	 at	which	 false‐positive	 LAC	 results	were	 obtained	 exceeded	
those	mentioned	in	the	package	inserts	of	the	evaluated	reagents	
up	to	where	included	inhibitors	should	neutralize	heparin	effects.
3.2 | Impact of AC on anti‐Xa activity and LAC assays
3.2.1 | AC concentration
Initial	anti‐Xa	activities	in	untreated	spiked	NPP	were	1.4,	1.5,	and	
1.3	 anti‐Xa	 IU/mL	 for	UFH,	enoxaparin,	 and	danaparoid,	 respec‐




The	 latter	 may	 be	 attributed	 to	 incomplete	 removal	 of	 high	 AC	
concentrations	after	 centrifugation	and	 subsequent	 interference	
with	the	chromogenic	anti‐Xa	assay	or	to	adsorption	of	water	by	























Table	 2	 summarizes	 dRVVT	 screen	 and	 PTT‐LA	 screen	 clotting	
times	measured	in	neat	NPP	and	NPP	spiked	with	UFH,	enoxaparin,	
and	 danaparoid	 at	 different	 anti‐Xa	 activity	 levels.	 Although	 in‐
cubation	 of	 plasma	 with	 AC	 did	 not	 alter	 interpretation	 of	 LAC	
results,	 changes	 in	 APTT	 screen	 clotting	 times	 were	 noticed.	
Consistently	 longer	 clotting	 times	 after	 AC	 were	 seen	 in	 UFH‐	
and	enoxaparin‐spiked	samples.	Differences	ranged	from	13.8	to	
52.8	seconds	for	UFH	(mean	difference,	23.6	±	3.8%)	and	from	1.8	
to	46.4	 seconds	 for	enoxaparin	 (mean	difference,	13.1	±	18.7%).	
















Before AC After AC
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LA	 reagent	 containing	HPE)	was	noticed	as	well,	 but	differences	
were	limited	compared	to	screening	tests	(mean	differences	before	















AC	proved	unable	 to	neutralize	 anti‐Xa	 activity	of	UFH,	 enoxaparin,	
and	danaparoid	 in	plasma	and	overcome	their	effect	on	LAC	testing.	
Furthermore,	 incubating	 samples	 with	 the	 AC	 product	 used	 in	 this	
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